Malignant Ovarian Germ Cell Tumor
Associated Genetic Biomarkers
NCI Definition: An invasive malignant neoplasm that arises from the ovary and originates from primordial germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, dysgerminoma, and non-gestational choriocarcinoma. 
Malignant ovarian germ cell tumors most frequently harbor alterations in PIK3CD, KRAS, TP53, TNFRSF14, and SPEN .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, KRAS Mutation, and TP53 Exon 7 Mutation are the most common alterations in malignant ovarian germ cell tumor .
There are 6 clinical trials for malignant ovarian germ cell tumor, of which 4 are open and 2 are completed or closed. Of the trials that contain malignant ovarian germ cell tumor as an inclusion criterion, 3 are phase 1 (3 open) and 3 are phase 2 (1 open).
HLA-A*02:01 is the most frequent gene inclusion criterion for malignant ovarian germ cell tumor clinical trials .
Aldesleukin, cyclophosphamide, and fludarabine are the most common interventions in malignant ovarian germ cell tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.